These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 699462)
1. Pharmacokinetics of lorcainide in man: a new antiarrhythmic agent. Klotz U; Müller-Seydlitz P; Heimburg P Clin Pharmacokinet; 1978; 3(5):407-18. PubMed ID: 699462 [TBL] [Abstract][Full Text] [Related]
2. Disposition and antiarrhythmic effect of lorcainide. Klotz U; Müller-Seydlitz P; Heimburg P Int J Clin Pharmacol Biopharm; 1979 Apr; 17(4):152-8. PubMed ID: 376458 [TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and tissue distribution of the new antiarrhythmic agent lorcainide (R 15889) in rats. Klotz U; Golbs E Arzneimittelforschung; 1980; 30(4):619-21. PubMed ID: 7190402 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of the newer antiarrhythmic agents. Gillis AM; Kates RE Clin Pharmacokinet; 1984; 9(5):375-403. PubMed ID: 6437721 [TBL] [Abstract][Full Text] [Related]
5. Effect of enzyme induction on the disposition of lorcainide in rats following intravenous and oral administration. Plänitz V; Jähnchen E Arzneimittelforschung; 1984; 34(6):669-71. PubMed ID: 6541487 [TBL] [Abstract][Full Text] [Related]
6. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers. Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of the initiation of antiarrhythmic therapy with lorcainide. Winkle RA; Keefe DL; Rodriguez I; Kates RE Am J Cardiol; 1984 Feb; 53(4):544-51. PubMed ID: 6198895 [TBL] [Abstract][Full Text] [Related]
9. Metabolism of flecainide. Conard GJ; Ober RE Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of lorcainide, a new antiarrhythmic drug, in patients with cardiac rhythm disorders. Somani P Am J Cardiol; 1981 Jul; 48(1):157-63. PubMed ID: 7246437 [TBL] [Abstract][Full Text] [Related]
11. Lorcainide kinetics and protein binding in patients with end-stage renal disease. Somani P; Simon V; Gupta RK; King P; Shapiro RS; Stockard H Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):121-5. PubMed ID: 6715079 [TBL] [Abstract][Full Text] [Related]
12. Bioavailability and saturation of the presystemic metabolism of oral lorcainide therapy initiated in three different dose regimens. Amery WK; Heykants J; Bruyneel K; Terryn R Eur J Clin Pharmacol; 1983; 24(4):517-9. PubMed ID: 6861866 [TBL] [Abstract][Full Text] [Related]
13. Preclinical and clinical pharmacokinetics of pirmenol. Chang T Am J Cardiol; 1987 Jun; 59(16):15H-19H. PubMed ID: 2438922 [TBL] [Abstract][Full Text] [Related]
14. Pharmacology of lorcainide. Keefe DL Am J Cardiol; 1984 Aug; 54(4):18B-21B. PubMed ID: 6465043 [TBL] [Abstract][Full Text] [Related]
15. Prehepatic and hepatic first-pass metabolism of lorcainide in rats. Plänitz V; Grönniger J; Jähnchen E Arzneimittelforschung; 1985; 35(6):923-6. PubMed ID: 4026917 [TBL] [Abstract][Full Text] [Related]